Virbac Reports Strong Revenue Growth and EBIT Margin for First Half of 2026
In the rapidly evolving animal health industry, Virbac has shown impressive resilience and growth, revealing a robust revenue growth of 7.4% along with an adjusted EBIT margin of 18.8% during the first semester of 2026. This growth not only sets a positive tone for the company but indicates its solid operational strategies and market responsiveness.
The revenue growth can be attributed to both the companion animal segment, which surged by 10%, and the livestock segment, which experienced a commendable increase of 6.7%. This success is notably supported by the performance of Virbac's 'Supercharge' platforms, which saw a substantial increase approximate to 12%, excluding Thyronorm contributions.
The strategic focus on enhancing product offerings and pricing adjustments, which averaged a 2% increase, complemented the substantial volume and mix effects that accounted for a growth of around 5.4%. The operational margin saw an increment of 0.5 percentage points compared to the same period last year, reflecting a favorable gross margin mix despite rising operational expenses, primarily due to seasonal distribution effects.
Virbac's consolidated net profit also showed a healthy increase of 5.9%, reaching €87.1 million. However, the net debt of the company as of June 2026 rose to €196 million from €173 million in December 2025, primarily prompted by the seasonal capital requirement trends. Despite this increase in debt, the company remains confident in maintaining strong financial health.
Looking ahead, Virbac has affirmed its revenue forecast for 2026, aiming for the upper end of its initial growth target, estimating between 5.5% and 7.5% in CERS. Furthermore, it anticipates an adjusted operating profit margin of around 17% for the year.
CEO Paul Martingell expressed optimism about the company’s performance, highlighting the 7.4% organic growth and solid operational margin of 18.8%. He noted that this performance underscores the team's ability to translate their commitment to animal health into tangible value, further reinforced by the scalability of the Supercharge platforms and seamless integration of Thyronorm.
Virbac's ambitious 'Growing Together' 2030 strategy continues to guide its operations, ensuring that the company is not only meeting its annual objectives but also has a strong foundation for future growth. As a pioneering force in animal health, Virbac’s strategies and performance metrics reveal its ability to adapt and flourish in a competitive marketplace.
As Virbac continues to navigate through the complexities of the animal healthcare sector, its solid performance in the first half of 2026 sets a promising precedent for future endeavors. With a keen eye on growth while adhering to its core mission of improving animal health, Virbac is well-positioned to maintain its trajectory in the evolving landscape of the industry.
Breakdown of Revenue Growth
The revenue growth can be attributed to both the companion animal segment, which surged by 10%, and the livestock segment, which experienced a commendable increase of 6.7%. This success is notably supported by the performance of Virbac's 'Supercharge' platforms, which saw a substantial increase approximate to 12%, excluding Thyronorm contributions.
The strategic focus on enhancing product offerings and pricing adjustments, which averaged a 2% increase, complemented the substantial volume and mix effects that accounted for a growth of around 5.4%. The operational margin saw an increment of 0.5 percentage points compared to the same period last year, reflecting a favorable gross margin mix despite rising operational expenses, primarily due to seasonal distribution effects.
Financial Highlights
Virbac's consolidated net profit also showed a healthy increase of 5.9%, reaching €87.1 million. However, the net debt of the company as of June 2026 rose to €196 million from €173 million in December 2025, primarily prompted by the seasonal capital requirement trends. Despite this increase in debt, the company remains confident in maintaining strong financial health.
Future Outlook
Looking ahead, Virbac has affirmed its revenue forecast for 2026, aiming for the upper end of its initial growth target, estimating between 5.5% and 7.5% in CERS. Furthermore, it anticipates an adjusted operating profit margin of around 17% for the year.
CEO Paul Martingell expressed optimism about the company’s performance, highlighting the 7.4% organic growth and solid operational margin of 18.8%. He noted that this performance underscores the team's ability to translate their commitment to animal health into tangible value, further reinforced by the scalability of the Supercharge platforms and seamless integration of Thyronorm.
Virbac's ambitious 'Growing Together' 2030 strategy continues to guide its operations, ensuring that the company is not only meeting its annual objectives but also has a strong foundation for future growth. As a pioneering force in animal health, Virbac’s strategies and performance metrics reveal its ability to adapt and flourish in a competitive marketplace.
Conclusion
As Virbac continues to navigate through the complexities of the animal healthcare sector, its solid performance in the first half of 2026 sets a promising precedent for future endeavors. With a keen eye on growth while adhering to its core mission of improving animal health, Virbac is well-positioned to maintain its trajectory in the evolving landscape of the industry.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.